What is HC Wainwright’s Estimate for KPTI FY2024 Earnings?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – HC Wainwright lifted their FY2024 earnings estimates for Karyopharm Therapeutics in a research note issued on Tuesday, November 5th. HC Wainwright analyst E. White now expects that the company will earn ($1.06) per share for the year, up from their previous forecast of ($1.07). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.95) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q4 2024 earnings at ($0.30) EPS, FY2025 earnings at ($1.06) EPS and FY2026 earnings at ($0.53) EPS.

Several other equities research analysts have also issued reports on the stock. StockNews.com lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $3.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. Piper Sandler increased their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Robert W. Baird reduced their price objective on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Karyopharm Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Stock Down 0.6 %

NASDAQ:KPTI opened at $0.88 on Friday. The firm has a market capitalization of $109.88 million, a PE ratio of -0.77 and a beta of 0.16. Karyopharm Therapeutics has a twelve month low of $0.62 and a twelve month high of $1.95. The stock’s 50-day simple moving average is $0.81 and its 200 day simple moving average is $0.90.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.01. The firm had revenue of $38.78 million for the quarter, compared to analyst estimates of $37.86 million. During the same quarter in the prior year, the firm earned ($0.30) earnings per share.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of institutional investors have recently made changes to their positions in KPTI. GSA Capital Partners LLP increased its position in Karyopharm Therapeutics by 80.6% during the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock valued at $1,474,000 after purchasing an additional 792,283 shares during the period. Exchange Traded Concepts LLC increased its position in Karyopharm Therapeutics by 34.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after buying an additional 56,613 shares in the last quarter. Point72 DIFC Ltd acquired a new position in shares of Karyopharm Therapeutics during the second quarter worth approximately $31,000. Cubist Systematic Strategies LLC acquired a new position in Karyopharm Therapeutics during the second quarter worth $494,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth about $143,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).